Maria E Due-Hansen
Overview
Explore the profile of Maria E Due-Hansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen S, Christiansen E, Urban C, Hudson B, Stocker C, Due-Hansen M, et al.
J Med Chem
. 2016 Mar;
59(6):2841-6.
PMID: 26928019
The free fatty acid receptor 1 (FFA1 or GPR40) is established as an interesting potential target for treatment of type 2 diabetes. However, to obtain optimal ligands, it may be...
2.
Due-Hansen M, Pandey S, Christiansen E, Andersen R, Hansen S, Ulven T
Org Biomol Chem
. 2015 Nov;
14(2):430-433.
PMID: 26586516
A protocol for amide coupling by in situ formation of acyl fluorides and reaction with amines at elevated temperature has been developed and found to be efficient for coupling of...
3.
Christiansen E, Due-Hansen M, Urban C, Merten N, Pfleiderer M, Karlsen K, et al.
ACS Med Chem Lett
. 2014 Jun;
1(7):345-9.
PMID: 24900217
The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic β-cells and amplifies glucose-stimulated insulin secretion, has emerged as an attractive target for the treatment...
4.
Hudson B, Due-Hansen M, Christiansen E, Hansen A, MacKenzie A, Murdoch H, et al.
J Biol Chem
. 2013 Apr;
288(24):17296-312.
PMID: 23589301
FFA2 is a G protein-coupled receptor that responds to short chain fatty acids and has generated interest as a therapeutic target for metabolic and inflammatory conditions. However, definition of its...
5.
Wagner R, Kaiser G, Gerst F, Christiansen E, Due-Hansen M, Grundmann M, et al.
Diabetes
. 2013 Feb;
62(6):2106-11.
PMID: 23378609
The role of free fatty acid receptor 1 (FFAR1/GPR40) in glucose homeostasis is still incompletely understood. Small receptor agonists stimulating insulin secretion are undergoing investigation for the treatment of type...
6.
Christiansen E, Due-Hansen M, Urban C, Grundmann M, Schmidt J, Hansen S, et al.
J Med Chem
. 2013 Jan;
56(3):982-92.
PMID: 23294321
The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2...
7.
Christiansen E, Due-Hansen M, Urban C, Grundmann M, Schroder R, Hudson B, et al.
J Med Chem
. 2012 Jun;
55(14):6624-8.
PMID: 22724451
FFA1 (GPR40) is a new target for treatment of type 2 diabetes. We recently identified the potent FFA1 agonist TUG-469 (5). Inspired by the structurally related TAK-875, we explored the...
8.
Christiansen E, Urban C, Grundmann M, Due-Hansen M, Hagesaether E, Schmidt J, et al.
J Med Chem
. 2011 Aug;
54(19):6691-703.
PMID: 21854074
The free fatty acid receptor 1 (FFA1, also known as GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and is recognized as an interesting new target for treatment of type...
9.
Schmidt J, Liebscher K, Merten N, Grundmann M, Mielenz M, Sauerwein H, et al.
J Biol Chem
. 2011 Feb;
286(14):11890-4.
PMID: 21339298
Among dietary components, conjugated linoleic acids (CLAs) have attracted considerable attention as weight loss supplements in the Western world because they reduce fat stores and increase muscle mass. However, a...
10.
Christiansen E, Due-Hansen M, Ulven T
J Org Chem
. 2010 Jan;
75(4):1301-4.
PMID: 20099863
A protocol for rapid and efficient Pd/Cu-catalyzed coupling of aryl bromides and iodides to terminal alkynes has been developed with use of 2-(di-tert-butylphosphino)-N-phenylindole (cataCXium PIntB) as ligand in TMEDA and...